Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 436)
Posted On: 06/30/2022 12:24:29 PM
Post# of 154728
Avatar
Posted By: Drano
Novo Nordisk's NASH drug is WORSE than placebo -- yet they say it's "on track. "

Quote:
In the study of 71 NASH patients with compensated cirrhosis (the F4 stage of the disease), only 10.6% of those who received a weekly 2.4 mg dose of semaglutide saw an improvemen t in liver fibrosis coinciding with no worsening of NASH. The figure for those on placebo was 29.2%.

As a secondary endpoint, 34% of patients on semaglutide saw a resolution of NASH—which means improvement in liver inflammation and liver cell ballooning—versus 20.8% on placebo.



https://www.fiercepharma.com/pharma/after-pha...-fail-nash













(4)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site